Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Author:

Berenguer‐Ruiz Sonsoles1ORCID,Aparicio‐Domínguez Mario1,Herranz‐Pinto Pedro2,Ruíz‐Villaverde Ricardo3,López‐Ferrer Anna4ORCID,Santos‐Juanes Jorge5,Rodríguez Fernández‐Freire Lourdes6,Hospital‐Gil Mercedes7,Arias‐Santiago Salvador8ORCID,Carretero‐Hernández Gregorio9,Mateu‐Puchades Almudena10,Ferran Marta11,del Alcázar Elena12ORCID,Santos‐Alarcón Sergio13,Garcia‐Latasa de Aranibar Francisco Javier14,Belinchón‐Romero Isabel15ORCID,González‐Cantero Álvaro16ORCID,Ruíz‐Genao Diana17ORCID,Eiris‐Salvado Noemí18,Rocamora‐Durán Vicenç19,Rivera‐Diaz Raquel20ORCID,de la Cueva Pablo21ORCID,Daudén Esteban1ORCID,Salgado‐Boquete Laura22,Llamas‐Velasco Mar1ORCID,

Affiliation:

1. Department of Dermatology Hospital Universitario de la Princesa Madrid Spain

2. Department of Dermatology Hospital Universitario La Paz Madrid Spain

3. Department of Dermatology Hospital Universitario San Cecilio Granada Spain

4. Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain

5. Department of Dermatology Hospital Universitario Central de Asturias Oviedo Spain

6. Department of Dermatology Hospital Virgen del Rocio Sevilla Spain

7. Department of Dermatology Hospital Universitario Puerta de Hierro Majadahonda Spain

8. Department of Dermatology Hospital Virgen de las Nieves Hospital Granada Spain

9. Department of Dermatology Hospital Universitario de Gran Canaria Dr. Negrín Las Palmas Spain

10. Department of Dermatology Hospital Universitari Doctor Peset Valencia Spain

11. Department of Dermatology Hospital del Mar Barcelona Spain

12. Department of Dermatology Hospital Universitari Germans Trias i Pujol Badalona Spain

13. Department of Dermatology Hospital Virgen de los Lirios Alcoy Spain

14. Department of Dermatology Hospital Royo Villanova Hospital Zaragoza Spain

15. Department of Dermatology Hospital General Universitario de Alicante Alicante Spain

16. Department of Dermatology Complejo Hospitalario de Toledo Toledo Spain

17. Department of Dermatology Hospital Universitario Fundación Alcorcon Madrid Spain

18. Department of Dermatology Complejo Asistencial Universitario de León León Spain

19. Department of Dermatology Hospital de Manacor Palma de Mallorca Spain

20. Department of Dermatology Hospital Universitario 12 de Octubre Madrid Spain

21. Department of Dermatology Hospital Universitario Infanta Leonor Madrid Spain

22. Department of Dermatology Hospital Universitario de Pontevedra Pontevedra Spain

Abstract

AbstractBackgroundTildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate‐to‐severe plaque psoriasis. Real‐world evidence on the effectiveness and safety of tildrakizumab is limited.ObjectivesTo assess the effectiveness and safety of tildrakizumab at 24 weeks in patients with moderate‐to‐severe plaque psoriasis in routine clinical practice.MethodsRetrospective, observational, multicentre study including adult patients with moderate‐to‐severe plaque psoriasis treated with tildrakizumab under real‐life conditions. Patient data were extracted from anonymized electronic medical records. Statistical analysis was performed using SPSS22.ResultsA total of 190 patients were included. About 53.9% were men with a mean age of 51.45 (SD 3.9) and a mean BMI of 29.13 (SD 6.21). About 79.8% (132 out of 190) of patients had previously received biological therapy (BT) and 17.3% (33 out of 191) had psoriatic arthritis. Baseline PASI was 10.7 (SD 6.53). Up to 109 patients reached Week 24 and at this point mean baseline PASI decreased to 1.7 (SD 4.8), representing an 88.79% mean PASI reduction. At 6 months, 87.1% and 40.3% of the treated patients achieved PASI ≤3 and ≤1, respectively. At Week 24 mean BSA decreased from 13.2 (SD 10.07) to 1.6 (SD 4.40) and mean DLQI went from 12.5 (SD 7.12) to 1.2 (SD 3.27). Multivariate analysis showed no differences when effectiveness was correlated with gender, obesity, psoriatic arthritis or prior exposure to BT. The rate of adverse events (AE) was 5.9% (11 out of 190), where infections were the most frequent AE (4 out of 11). One patient suffered a haemorrhagic ictus and one patient died due to causes unrelated to the study.ConclusionTildrakizumab was effective and safe in a large cohort of patients with moderate‐to‐severe plaque psoriasis treated in a routine clinical setting.

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3